Portal de Periódicos da CAPES

Artigo Produção Nacional Revisado por pares

BIBTEX RIS

The effects of long-term exposure to disease-modifying drugs during pregnancy in multiple sclerosis

2012; Elsevier BV; Volume: 115; Issue: 2 Linguagem: Inglês

10.1016/j.clineuro.2012.04.024

1872-6968

Yára Dadalti Fragoso, Mike Boggild, Miguel Ángel Macías-Islas, Adriana Carrá, K Schaerer, Adriana Aguayo, Sandra Maria Garcia de Almeida, Marcos Papais Alvarenga, Regina Maria Papais Alvarenga, Soniza Vieira Alves‐Leon, Walter Oleschko Arruda, Joseph Bruno Bidin Brooks, Elizabeth Regina Comini-Frota, Maria Lúcia Brito Ferreira, Alessandro Finkelsztejn, Juliana Finkelsztejn, Lucas Dias de Freitas, Andre Serafin Gallina, Paulo Diniz da Gama, Sergio Georgetto, Maria Cristina B. Giacomo, Sidney Gomes, Marcus Vinícius Magno Gonçalves, Anderson Kuntz Grzesiuk, Damacio Ramón Kaimen-Maciel, Josiane Lopes, Giselle Lourenço, Fabíola Rachid Malfetano, Nívea Macedo Oliveira Morales, Rogério de Rizo Morales, Celso Luis Silva Oliveira, P. Onaha, Cristiane Borges Patroclo, Steve Biko Menezes Hora Alves Ribeiro, T.A.G.J. Ribeiro, Heidi Salminen, Patrícia Santoro, Marcos Seefeld, Paula Vallegas Soares, Adriana Tarulla, Cláudia Cristina Ferreira Vasconcelos,

Multiple Sclerosis Research Studies

Women with multiple sclerosis (MS) who intend to get pregnant are often advised to discontinue disease modifying therapy (DMT) prior to conception. This recommendation is not based on medical evidence and may interfere with disease control by immunomodulatory drugs. The present study was designed to help discuss the effect of DMT for MS on pregnancy and on disease course. Retrospective data from 152 pregnancies of 132 women with MS were collected by the physician in charge of the case. All data were entered into a specific file for qualitative and quantitative statistical analysis. From the total group of patients, 89 pregnancies occurred without any exposure to MS drugs, while 61 pregnancies occurred with at least eight weeks of exposure to MS immunomodulatory drugs. The rate of obstetric and neonatal complications was similar in both groups, except for the newborn weight and height which was smaller for mothers receiving medications. Mothers' post-delivery relapse rate and EDSS scores in the follow-up period were significantly higher in the absence of treatment. It is possible that, with further such supportive data, international guidelines on MS treatment in young women who intend to get pregnant may need to be revised.